DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Paul - 1 he'd - 1 who's - 1 He's - 1 doesn't - 1 Nobody - 1 didn't - 1 Matthew McCoy - 1
Top related locs:
Hims Shanghai China Europe London Singapore
Top related orgs:
View Research - 1 Department of Medical - 1 University of Pennsylvania - 1 UCLA's Fielding School of Public Health - 1 Northwestern University's Feinberg School of Medicine - 1 telemedicine - 1 of Justice - 1 Business - 1

Search resuls for: "— Pharmaceutical"


3 mentions found


☆ Online Health Providers Are Making Money on Young Men's Sense of Shame
  + stars: | 2024-07-18 | by ( Emily Stewart | ) www.businessinsider.com   time to read: +11 min
The pandemic accelerated the rise of telehealth, which these DTC companies are a part of both culturally and legally. Hims & Hers Health has a market cap of over $4 billion. Those at the forefront of the DTC health revolution have American guys right where they want them: insecure, on edge, and ready to open their wallets. Plenty of doctors have sounded the alarm about DTC telehealth companies, and some firms have gotten into legal trouble, too. For all the issues with DTC companies, it's fair to note that traditional healthcare settings are far from perfect.
Persons: Paul, he'd, who's, He's, doesn't, Nobody, didn't, Matthew McCoy, what's, Ashwini Nagappan, Joshua Halpern, Halpern, Nagappan, McCoy, Hims, —, you've, They're, men's, Ro, Emily Stewart Organizations: View Research, Department of Medical, University of Pennsylvania, UCLA's Fielding School of Public Health, Northwestern University's Feinberg School of Medicine, telemedicine, of Justice, Business Locations: Hims
☆ AstraZeneca targets $80 billion in total revenue by 2030 in 'post-Covid era'
  + stars: | 2024-05-21 | by ( Sophie Kiderlin | In | ) www.cnbc.com   time to read: +2 min
Costfoto | Future Publishing | Getty ImagesLONDON — Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023. AstraZeneca will focus on its oncology, biopharmaceuticals and rare diseases businesses and expects to release an additional 20 medicines in the next six years. "Many of them have the potential to be $5 billion drugs," Sarin noted. A company statement detailed that this revenue figure could be hit annually for many of the new medicines in peak years. "For the entire market to get replaced it will take time, but we think we have the technology today to start replacing them," Sarin told CNBC.
Persons: CNBC's Arabile Gumede Organizations: Astrazeneca, Artificial Intelligence, — Pharmaceutical, AstraZeneca, CNBC, U.S . FDA, Pharmaceuticals, Investments Locations: Shanghai, China, Europe, London, Singapore
☆ Johnson & Johnson deserves more credit for another healthy quarter and strong guidance
  + stars: | 2023-01-24 | by ( Jeff Marks | ) www.cnbc.com   time to read: +6 min
Johnson & Johnson (JNJ) posted another solid quarter of healthy growth — and another productive year of free-cash-flow generation — despite a slight miss on sales. On an adjusted operational basis, which excludes the impact of acquisitions and divestitures and currency, sales rose 0.8%. But the new year has been tough on pharmaceutical stocks and almost all of health care, including JNJ stock, which is down 6% year to date. Johnson & Johnson forecasts adjusted EPS on an operational basis to grow 2.5% to 4.5%, which at a midpoint of $10.50 compares favorably to the consensus of $10.33. Its addition to the MedTech division is expected to help accelerate sales growth this year.
0 next >>
Total: 3